U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07516561) titled 'Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia.' on April 01.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
Study Start Date: July 07, 2026
Study Type: INTERVENTIONAL
Condition:
Alopecia, Androgenetic
Intervention:
DRUG: APSMNF 1
Administer twice a day during 24 weeks.
DRUG: APSMNF 2
Administer twice a day during 24 weeks.
DRUG: Eniagor(R)
Administer twice a day during 24 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Apsen Farmaceutica S.A.
Published by HT Digital Content Services with perm...